REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $36.00.Stay ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has inked an agreement with a Japanese drug company to get two of its treatment candidates to market — a deal that could be worth $810 million over time.

Regenxbio Inc (RGNX) stock saw a modest uptick, ending the day at $7.05 which represents a slight increase of $0.10 or 1.44% from the prior close of $6.95. The stock opened at $7.17 and touched a low ...

AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular ...

Plus: Rockville gene therapy company inks deal; Pioneering politician from Montgomery County celebrated with portrait ...